Viewing Study NCT06250764



Ignite Creation Date: 2024-05-06 @ 8:06 PM
Last Modification Date: 2024-10-26 @ 3:20 PM
Study NCT ID: NCT06250764
Status: COMPLETED
Last Update Posted: 2024-02-09
First Post: 2024-02-01

Brief Title: Asprosin Adropin Irisin Levels in Periodontitis
Sponsor: AYSAN LEKTEMUR ALPAN
Organization: Pamukkale University

Study Overview

Official Title: Investigation the Relationship Between Periodontal Disease and Asprosin Adropin Irisin Levels
Status: COMPLETED
Status Verified Date: 2024-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The recently discovered association of the hormones asprosin adropin and irisin with obesity and metabolic status as well as the fact that periodontal diseases are affected by obesity and nutrition bilaterally have led us to investigate the relationship between selected target markers and periodontal disease The primary aim and main objective of this study is to increase the knowledge and to direct future researches as a result of the lack of adequate research in the past and the very limited investigations with these hormones in dentistry and periodontology

Our study was conducted on 122 patients who applied to Adıyaman University Faculty of Dentistry and were referred to the Department of Periodontology for routine periodontal controls Participants gender age height weight BMI education level tooth brushing and flossing habits as well as clinical parameters PI GI SCD CAS and SDI were noted Participants were divided into 4 groups as healthy gingivitis initial periodontitis and advanced periodontitis and grouped according to the current periodontal classification of 2017 DOS was collected from the groups for examination and asprosin adropin and irisin values in the samples were evaluated by ELISA test
Detailed Description: A total of 122 patients participated in the study All patients participating in the trial received written and verbal information about the purpose and method of the study and signed consent Patients with cardiovascular disease liver and kidney disease metabolic disorders diabetes asthma thyroid dysfunction who used antibiotics or anti-inflammatory drugs within the last three months who received periodontal treatment within the last six months obese patients with body mass index BMI 30 kgm2 according to the reference range determined by the World Health Organization and patients who refused to participate were excluded from the study In order to calculate the BMI of the individuals included in the study height-weight information tooth brushing frequency in order to determine oral hygiene habits and educational status were also recorded to determine economic levels Age and gender were also noted Individuals aged 25-60 years were divided into four groups according to their periodontal status

The periodontal assessment was performed by a single trained examiner SD A graded periodontal probe Williams Hu-Friedy Chicago IL USA was used to measure probing depth PD which was determined as the depth from the gingival margin to the bottom of the gingival sulcusperiodontal pocket clinical attachment loss CAL which was calculated as the distance from the cemento-enamel junction to the bottom of the periodontal pocket and dual recording - of bleeding on probing BOP gingival index GI and plaque index PI in total except third molars To assess the intra-examiner calibration Cronbachs alpha was used and its value was 090 for PD and CAL measures Alveolar bone loss ABL was determined in each participant by orthopantomography The distance between the cemento-enamel junction and the bone crest was measured in both mesial and distal regions and its ratio to the root length was calculated to assess bone loss The periodontal status of the patients was evaluated based on the Classification of Periodontal and Peri-Implant Diseases and Conditions from the 2017 World Workshop Participants were classified into four distinct groups based on their periodontal conditions

1 Group 1 30 periodontally healthy individuals
2 Group 2 30 patients with gingivitis
3 Group 3 32 patients with generalized stage I and stage II periodontitis
4 Group 4 30 patients with generalized stage III and stage IV periodontitis An individual to be considered to have periodontal health according to this definition the percentage of sites with bleeding on probing should be no more than 10 and the probing depth should be 3 mm or less Patients with gingivitis had PD 3 mm BOP in 30 of the probing sites and no interproximal AL or radiographic bone loss Stage I periodontitis was diagnosed with interdental attachment loss AL ranging between 1 and 2 mm at the site of greatest loss Radiographic bone loss BL is limited to less than 15 and no tooth loss Additionally the maximum probing depth PD is equal to or less than 4 mm which primarily involves horizontal bone loss Stage II periodontitis was diagnosed with interdental attachment loss AL ranging between 3 and 4 mm at the site of greatest loss Radiographic bone loss BL extends to a range of 15 to 33 there is no tooth loss The maximum probing depth PD is equal to or less than 5 mm or primarily involves horizontal bone loss Stage III periodontitis is diagnosed when interdental attachment loss AL is 5 radiographic bone loss BL extends to the mid-third of the root and beyond and tooth loss may become evident 4 teeth Either PD 6 mm or vertical BL 3 mm or Class IIIII furcation involvement or moderate ridge defect Stage IV periodontitis is diagnosed with interdental attachment loss AL of 5 mm at the site of greatest loss with radiographic BL extending to the mid-third of the root and beyond 5 tooth losses due to periodontitis are evident In addition to Stage III either masticatory dysfunction secondary occlusal trauma tooth mobility degree 2 severe ridge defect bite collapse or teeth drifting and flaring

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None